Immune Phenotyping in Amyotrophic Lateral Sclerosis

Overview

About this study

The goals of this study are to identify biomarkers that allow improved staging or prognosis of the disease, and through the discovery of previously unrecognized immune abnormalities in ALS we aim to eventually identify immune therapies that may provide benefit in ALS.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inlcusion Criteria:

  • Patients with clinically-possible, probable, or definite ALS by El Escorial Criteria53
  • Ccognitive ability to provide informed consent
  • No depression (Beck Depression Inventory > 18)
  • Not ventilator-dependent

Exclusion Criteria:

  • Any significant medical condition determined by the investigator Malignancy
  • Active infection
  • Use of immune modulating or experimental therapy within 6 months of enrollment

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nathan Staff, M.D., Ph.D.

Open for enrollment

Contact information:

Michelle Turner

(507)284-1223

Turner.Michelle@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available